We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Skc5.5
Skullcap Research
Mostly mechanism / observationalHigh safety
48 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Skullcap studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality randomised trials published 2009–2026 with a typical study size of 59 participants.
Based on 48 studies · 4 RCTs · 289 total participants
Confidence
Moderate
What the studies found
1helped· 47 more without graded effect data
By outcome
Therapeutic & clinical
Mostly mechanism / observational21 studies
Safety profile
Mostly mechanism / observational6 studies
Inflammation
Mostly mechanism / observational5 studies
Anxiety & stressReduced nervous tension and anxiety · 30-60 minutes acute; 2-4 weeks cumulative · Soothing of the stress response and nervous tension · 1-3 weeks
Mostly mechanism / observational4 studies
Neuroprotection & brain aging
Mostly mechanism / observational4 studies
Heart & blood pressure
Mostly mechanism / observational3 studies
Joint pain & arthritis
Mostly mechanism / observational3 studies
Depression & moodNervine effects support emotional calm and stress resilience · 2-4 weeks
1Cardiac health restoration following myocardial ischemia-reperfusion injurySystematic ReviewCited 3×2025
Research in both animal and cell models suggests that these flavonoids, especially baicalin, can restore cardiac health following MIRI, improving cardiac performance, and reducing cardiac damage.
Nasiri R et al. · Tissue & cell (2025)
Research in both animal and cell models suggests that these flavonoids, especially baicalin, can restore cardiac health following MIRI, improving cardiac performance, and reducing cardiac damage.
These findings underscore the potential of baicalin and baicalein as therapeutic options for MIRI.
However, further research and clinical trials are necessary to elucidate their mechanisms fully and to develop baicalin into a viable treatment.
2Pharmacological activity of baicaleinSystematic ReviewCited 23×2023
In this review, we summarized the latest reports on one of the most important aglycones with respect to the pharmacological activity and high content in Baikal skullcap, which is 5,6,7-trihydroxyflavone (baicalein).
Chmiel M et al. · International journal of molecular sciences (2023)
It has been documented that the extract of Baikal skullcap (Scutellaria baicalensis) has hepatoprotective, calming, antiallergic, and anti-inflammatory properties.
Flavonoid compounds found in the extract, including baicalein, have strong antiradical activity, which improves overall health and increases feelings of well-being.
Plant-derived bioactive compounds with antioxidant activity have for a long time been used as an alternative source of medicines to treat oxidative stress-related diseases.
This review will encourage researchers to generalize the merits of wogonin to be used as potential compound for cancer treatment.
Tuli HS et al. · Experimental biology and medicine (Maywood, N.J.) (2023)
This review focuses on a complete overview of published reports that suggest chemopreventive action of wogonin and the mechanistic insights behind these neoplastic activities.
It also emphasizes the synergistic improvements made by wogonin in chemoprevention.
The factual data in this mini-review stimulate additional research on chemistry and toxicological profile of wogonin to confirm its safety issues.
4Cancer prevention and treatment efficacySystematic ReviewCited 112×2022
These studies propound the use of WOG as a potential anticancer candidate; however, further high-quality studies are required to firmly establish the clinical efficacy of WOG for the prevention and treatment of human malignancies.
Banik K et al. · Phytotherapy research : PTR (2022)
WOG, in combination with established chemotherapeutic drugs, improves the efficacy of treatment and lowers toxicity.
Nevertheless, human trials are warranted to validate these findings.
Numerous preclinical studies, combined with an extensive margin of safety and no severe side effects, underscore WOG's therapeutic potential as an anticancer drug.
Flavocoxid may therefore provide a potential therapeutic approach to the treatment of chronic inflammatory conditions.
Bitto A et al. · Mediators of inflammation (2014)
Flavocoxid is a mixed extract containing baicalin and catechin and it acts as a dual balanced inhibitor of cyclooxygenase-1 (COX-1) and COX-2 peroxidase enzyme activities with a significant inhibition of 5-lipoxygenase (5-LOX) enzyme activity in vitro.
Flavocoxid downregulates gene or protein expression of several inflammatory markers and exerts also strong antioxidant activity in several experimental models.
Controlled clinical trials and a postmarketing study have clearly shown that flavocoxid is as effective as naproxen in managing the signs and symptoms of osteoarthritis of the knee and it has better upper gastrointestinal, renal, and respiratory safety profile than naproxen.
It is with hope that the therapeutic potential of these flavonoids can be utilized and developed as natural treatments for ischemia-induced injuries of the central nervous system (CNS).
Pan L et al. · Oxidative medicine and cellular longevity (2021)
They have been demonstrated to exert promising pharmacological capabilities in preventing cell and tissue damage.
This review focuses on the therapeutic potentials of these flavonoids against ischemia-induced neurotoxicity and damage in the brain and retina.
The bioactivity and bioavailability of baicalein, baicalin, and wogonin are also discussed.
8Relaxation and anxiolytic actionSystematic ReviewCited 1×2009
While questions remain in the literature regarding the medicinal value of these supplements in treating mood and anxiety disorders, based on cellular and animal studies as well as human clinical trials the literature supports a role for these preparations as useful alternatives in the management of the stress and anxiety of everyday life.
Weeks BS · Medical science monitor : international medical journal of experimental and clinical research (2009)
Further, extracts of Magnolia and Phellondendron bark are mild sedatives.
Supplements such as gamma-aminobutyric acid (GABA), theanine, tryptophan and 5-hydroxytryptophan (5-HTP) are reported to promote relaxation.
In general, these supplements appear to act as GABA receptor agonists or to boost GABA levels, although Kava inhibits both norephinephrine uptake and sodium and potassium channels and 5-HTP may act through elevation of serotonin.
9CrossoverCited 1×n=43 · small study2025
The herbal supplement is safe and enhances mood, reduces subjective anxiety, and improves cognition under stress, though cognitive effects are variable without stress exposure.The study was registered on clinicaltrials.gov (identifier: NCT05757050).
Dodd F et al. · Journal of psychopharmacology (Oxford, England) (2025)
A higher proportion of subjects experienced ⩾30% gains in social satisfaction scores after 7 days.
The herbal supplement is safe and enhances mood, reduces subjective anxiety, and improves cognition under stress, though cognitive effects are variable without stress exposure.The study was registered on clinicaltrials.gov (identifier: NCT05757050).
10Total Mood DisturbanceCrossoverCited 18×n=43 · small study2014
However, as S. lateriflora significantly enhanced global mood without a reduction in energy or cognition, further study assessing its putative anxiolytic effects in notably anxious subjects with co-morbid depression is warranted.
Brock C et al. · Phytotherapy research : PTR (2014)
Likely real
In this relatively non-anxious population (81% were mildly anxious or less, i.e.
However, there was a significant group effect (p = 0.049), suggesting a carryover effect of skullcap.
For Total Mood Disturbance measured by the Profile of Mood States, there was a highly significant (p = <0.001) decrease from pre-test scores with skullcap but not placebo (p = 0.072).
This review bridges traditional MFH principles with cutting-edge research, positioning baicalin as a promising candidate for functional food development and preventive healthcare, aligned with global trends in natural product utilization and sustainable therapeutics.
Xu CQ et al. · Naunyn-Schmiedeberg's archives of pharmacology (2026)
Challenges such as low water solubility (0.5 mg/mL) and pH-dependent stability are addressed through innovative formulations, such as β-cyclodextrin complexes and ternary solvent systems, which enhance solubility by sevenfold.
Network pharmacology and bioinformatics analyses reveal baicalin's multi-target engagement in cardiovascular, metabolic, and neurological disorders, underscoring its therapeutic versatility.
Clinically, baicalin demonstrates cardioprotective, antidiabetic, and neuroprotective efficacy, while nano-delivery systems-including liposomes and metal-organic frameworks-overcome bioavailability limitations.
This review aims to furnish a thorough academic understanding and a solid theoretical foundation for the further research and development of SLPs as therapeutic agents and multifunctional biomaterials, thereby establishing a scientific basis for innovation in novel drugs and functional foods derived from Scutellaria.
Zhao F et al. · Carbohydrate research (2026)
Additionally, we emphasize the chemical and structural diversity of SLPs, the specificity of their biological activities, and the key structure-activity relationships (SARs) that determine their pharmacological effects.
We also address the challenges and opportunities associated with the application of SLPs in the food, pharmaceutical, and cosmetic sectors, while critically examining potential development trends and future research directions.
This systematic-review examined the effects of Skullcap.
Ning C et al. · Molecules (Basel, Switzerland) (2026)
To date, a large amount of research has been conducted on the antibacterial activity and related mechanisms of baicalin, making it a promising candidate for new broad-spectrum antibacterial drugs.
However, the solubility of baicalin is limited.
To improve its solubility and overcome the clinical application bottleneck, researchers have developed various solubilization techniques.
Continued work is needed to resolve formulation challenges and define precise molecular targets, but their trajectory reflects the growing scientific and clinical momentum around rationally designed natural compound therapeutics.
Capó X et al. · Seminars in oncology (2025)
Despite these pharmacokinetic limitations, baicalein and baicalin remain compelling candidates for integrative oncological approaches.
Their pleiotropic mechanisms, combined with low toxicity and synergistic behavior with standard therapies, position them as prototypes for a new generation of phytochemical-based anticancer agents.
Continued work is needed to resolve formulation challenges and define precise molecular targets, but their trajectory reflects the growing scientific and clinical momentum around rationally designed natural compound therapeutics.
Our aim is to provide a valuable reference for future research and clinical applications.
Meng X et al. · Molecules (Basel, Switzerland) (2025)
Documented mechanisms of action include disrupting the Escherichia coli membrane, downregulating quorum-sensing gene expression in Pseudomonas aeruginosa, and inhibiting host inflammatory pathways such as PI3K/Akt/NF-κB.
However, its clinical translation faces several bottlenecks, including reliance on animal experiment data, low bioavailability, and regulatory compliance issues.
Our aim is to provide a valuable reference for future research and clinical applications.
Future researchers need to further explore the long-term efficacy and safety of wogonin in clinical trials and translate it for early application in the clinical treatment of true CNS disorders.
Fu Q et al. · Brain research bulletin (2025)
However, despite the substantial preclinical evidence, further large-scale clinical studies are necessary.
Future researchers need to further explore the long-term efficacy and safety of wogonin in clinical trials and translate it for early application in the clinical treatment of true CNS disorders.
These findings highlight the potential of baiclalein as a complementary approach for managing neurodegenerative diseases, offering a safer and more holistic alternative to conventional therapies.
Kuwar OK et al. · Inflammopharmacology (2025)
Multiple pathological mechanisms drive this neuronal loss, including oxidative stress, chronic inflammation, mitochondrial dysfunction, protein misfolding, and excitotoxicity.
It exerts anti-inflammatory effects by inhibiting NFĸB activation, thereby reducing the production of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and NLRP3 inflammasome, and enzymes like COX-2, LOX, and iNOS, which are essential for innate and adaptive immune responses.
Simultaneously, baicalein enhances the Nrf2 activation, promoting the expression of antioxidant enzymes like HO-1, NQO1, GPx, and SOD, thus countering oxidative stress.
Importantly, this review examines the potential mechanisms by which OA may influence the gut-liver axis, hypothesizing that these interactions may confer health benefits associated with OA that transcend the limitations posed by its poor bioavailability.
Luo C et al. · Chinese journal of natural medicines (2025)
It encompasses the synthesis of active pharmaceutical ingredients, pharmacokinetics, pharmacological efficacy, toxicology, drug delivery, and recent advancements in clinical trials.
Importantly, this review examines the potential mechanisms by which OA may influence the gut-liver axis, hypothesizing that these interactions may confer health benefits associated with OA that transcend the limitations posed by its poor bioavailability.